Universität zu Köln

Callizo, Josep, Ziemssen, Focke, Bertelmann, Thomas, Feltgen, Nicolas, Voegeler, Jessica, Koch, Mirja, Eter, Nicole, Liakopoulos, Sandra, Schmitz-Valckenberg, Steffen and Spital, Georg (2019). Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clin. Ophthalmol., 13. S. 2167 - 2180. ALBANY: DOVE MEDICAL PRESS LTD. ISSN 1177-5483

Full text not available from this repository.

Abstract

Purpose: The non-interventional OCEAN study (NCT02194803) evaluated frequency and monitoring of ranibizumab injections for retinal vein occlusion (RVO) in routine practice in Germany. Methods: RVO patients (including branch and central RVO (BRVO/CRVO)) receiving ranibizumab were included. Best-corrected visual acuity (BCVA) testing, imaging and treatment were performed at the investigators' discretion and documented over 24 months. Results: Overall, 744 RVO patients (27% BRVO, 16% CRVO, remaining unspecified RVO) were included. For 74% of patients, data were available for the 12-month visit and for 56% for the 24-month visit. Mean baseline BCVA was 52.0 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (BRVO: 55.9, CRVO: 43.9). BCVA improved rapidly within the first 3 months, reaching 64.3 letters at 12 months and 64.7 at 24 months. CRVO patients showed less improvement than those with BRVO. Patients received a median of 4 (5) injections over 12 (24) months, with 100% of patients receiving injections at baseline, 70% at Month 1 and 81% at Month 2. Overall, 40% of patients demonstrated a >= 15 letter increase within the first 3 months (42% BRVO, 46% CRVO). Patients with low initial BCVA (<50 letters) showed greater improvement than patients with higher baseline BCVA. Due to considerable loss to follow-up, the number of injections and optical coherence tomography (OCT) examinations were not associated with the change in BCVA. Conclusion: Patients with RVO in routine practice in Germany received fewer injections and fewer OCT examinations than in clinical trials. CRVO patients showed less and later improvement compared to BRVO patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Callizo, Josep UNSPECIFIED UNSPECIFIED UNSPECIFIED Ziemssen, Focke UNSPECIFIED UNSPECIFIED UNSPECIFIED Bertelmann, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Feltgen, Nicolas UNSPECIFIED UNSPECIFIED UNSPECIFIED Voegeler, Jessica UNSPECIFIED UNSPECIFIED UNSPECIFIED Koch, Mirja UNSPECIFIED UNSPECIFIED UNSPECIFIED Eter, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED Liakopoulos, Sandra UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitz-Valckenberg, Steffen UNSPECIFIED UNSPECIFIED UNSPECIFIED Spital, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-160383
DOI:	10.2147/OPTH.S209253
Journal or Publication Title:	Clin. Ophthalmol.
Volume:	13
Page Range:	S. 2167 - 2180
Date:	2019
Publisher:	DOVE MEDICAL PRESS LTD
Place of Publication:	ALBANY
ISSN:	1177-5483
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MACULAR EDEMA SECONDARY; ANTI-VEGF TREATMENT; SUSTAINED BENEFITS; CLINICAL-PRACTICE; 12-MONTH OUTCOMES; VISUAL-ACUITY; FOLLOW-UP; THERAPY; DEXAMETHASONE; DEGENERATION Multiple languages Ophthalmology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16038